Latest market price and medical insurance coverage policy updates for Pitolisant in 2025

Pitolisant (Pitolisant) is a new H3 receptor antagonist /agonist used to treat narcolepsy (narcolepsy). It can improve patients' daytime sleepiness symptoms by regulating the arousal state of the central nervous system. In 2025, the original drug of tilorisen will be launched in China and included in medical insurance, providing patients with more accessible treatment options. Being included in medical insurance means that eligible patients can enjoy reimbursement according to the policy, thereby alleviating the financial pressure of long-term medication.

In terms of price, the original version of tilorisen on the domestic market is 4.5mg*30 tablets, and each box is priced at approximately 1,000 yuan. Due to medical insurance coverage, the patient's actual out-of-pocket amount will be reduced based on the reimbursement ratio, which greatly reduces the financial burden for narcolepsy patients who require long-term maintenance treatment. Doctors usually develop individualized dosage plans based on the patient's condition and drug tolerance to ensure efficacy and safety.

In overseas markets, generic drugs of tilorisan have also been launched. Taking the specifications of 18mg*30 tablets produced by Laos Pharmaceutical Factory as an example, each box sells for about 3,000 yuan, but the price will be affected by exchange rates and market fluctuations. The emergence of overseas generic drugs has provided additional options for some patients who cannot use domestic medical insurance drugs, but they still need to obtain them through formal channels in terms of quality and accessibility.

Overall, 2025 The price of tilorisen in the domestic market is relatively controllable, and it has been included in the medical insurance policy, improving the accessibility and affordability of the drug for patients. During use, patients should follow the doctor's instructions for long-term management, regularly review their condition and liver function indicators, and avoid changing doses or channels at will to ensure the therapeutic effect and medication safety.

Reference materials:https://www.drugs.com/

xa0